Anti-TNF agents and nail psoriasis: a single-center, retrospective, comparative study

References

• de Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de Kerkhof PC. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996;193:300–303.
   PubMed Web of Science ®Google Scholar
• de BD. Management of psoriatic nail disease. Semin Cutan Med Surg. 2009;28:39–43.
   PubMed Web of Science ®Google Scholar
• Gupta AK, Cooper EA. Psoriatic nail disease: quality of life and treatment. J Cutan Med Surg. 2009;13(Suppl 2):S102–S106.
   PubMedGoogle Scholar
• Lawry M. Biological therapy and nail psoriasis. Dermatol Ther. 2007;20:60–67.
   PubMed Web of Science ®Google Scholar
• Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol. 2009;23(Suppl 1):15–21.
   PubMed Web of Science ®Google Scholar
• Noiles K, Vender R. Nail psoriasis and biologics. J Cutan Med Surg. 2009;13:5.
   PubMed Web of Science ®Google Scholar
• Fabroni C, Gori A, Troiano M, Prignano F, Lotti T. Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients. J Eur Acad Dermatol Venereol. 2011;25:549–553.
   PubMed Web of Science ®Google Scholar
• Irla N, Yawalkar N. Marked improvement in nail psoriasis during treatment with adalimumab. Dermatology. 2009;219:353–356.
   PubMed Web of Science ®Google Scholar
• Luger TA, Barker J, Lambert J, Yang S, Robertson D, Foehl J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2009;23:896–904.
   PubMed Web of Science ®Google Scholar
• Reich K, Ortonne JP, Kerkmann U, Wang Y, Saurat JH, Papp K, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. Dermatology. 2010;221:172–178.
   PubMed Web of Science ®Google Scholar
• Rich P, Griffiths CE, Reich K, Nestle FO, Scher RK, Li S, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2008;58:224–231.
   PubMed Web of Science ®Google Scholar
• Sanchez-Regana M, Sola-Ortigosa J, Alsina-Gibert M, Vidal-Fernandez M, Umbert-Millet P. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). J Eur Acad Dermatol Venereol. 2011;25:579–586.
   PubMed Web of Science ®Google Scholar
• Marchesoni A, Altomare G, Matucci-Cerinic M, Balato N, Olivieri I, Salvarani C, et al. An Italian shared dermatological and rheumatological proposal for the use of biological agents in psoriatic disease. J Eur Acad Dermatol Venereol. 2010;24:578–586.
   PubMed Web of Science ®Google Scholar
• de Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de Kerkhof PC. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology. 1996;193:300–303.
   PubMed Web of Science ®Google Scholar
• Maejima H, Taniguchi T, Watarai A, Katsuoka K. Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index. Int J Dermatol. 2010;49:901–906.
   PubMed Web of Science ®Google Scholar
• Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol. 2009;23(Suppl 1):15–21.
   PubMed Web of Science ®Google Scholar
• Soy M, Karaca N, Umit EU, Bes C, Piskin S. Joint and nail involvement in Turkish patients with psoriatic arthritis. Rheumatol Int. 2008;29:223–225.
   PubMed Web of Science ®Google Scholar
• Williamson L, Dalbeth N, Dockerty JL, Gee BC, Weatherall R, Wordsworth BP. Extended report: nail disease in psoriatic arthritis–clinically important, potentially treatable and often overlooked. Rheumatology (Oxford). 2004;43:790–794.
   PubMed Web of Science ®Google Scholar
• Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61:233–239.
   PubMed Web of Science ®Google Scholar
• Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003;49:206–212.
   PubMed Web of Science ®Google Scholar
• Reich AK, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomised controlled trials. Br J Dermatol. 2011 [Epub ahead of print].
   Web of Science ®Google Scholar
• Reich K, Sinclair R, Roberts G, Griffiths CE, Tabberer M, Barker J. Comparative effects of biological therapies on the severity of skin symptoms and health-related quality of life in patients with plaque-type psoriasis: a meta-analysis. Curr Med Res Opin. 2008;24:1237–1254.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Schmitt J, Wozel G, Kirch W. Treatment of plaque psoriasis with biologics. A meta-analysis of randomized controlled trials. Med Klin (Munich). 2009;104:125–136.
   PubMed Web of Science ®Google Scholar
• Sanchez-Regana M, Sola-Ortigosa J, Alsina-Gibert M, Vidal-Fernandez M, Umbert-Millet P. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). J Eur Acad Dermatol Venereol. 2011;25:579–586.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–1374.
   PubMed Web of Science ®Google Scholar
• Rich P, Griffiths CE, Reich K, Nestle FO, Scher RK, Li S, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2008;58:224–231.
   PubMed Web of Science ®Google Scholar
• Reich K, Ortonne JP, Kerkmann U, Wang Y, Saurat JH, Papp K, et al. Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial. Dermatology. 2010;221:172–178.
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Gregoriou S, Stratigos A, Larios G, Korfitis C, Papaioannou D, et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol. 2008;159:453–456.
   PubMed Web of Science ®Google Scholar
• Fabroni C, Gori A, Troiano M, Prignano F, Lotti T. Infliximab efficacy in nail psoriasis. A retrospective study in 48 patients. J Eur Acad Dermatol Venereol. 2011;25:549–553.
   PubMed Web of Science ®Google Scholar
• Van den Bosch F, Manger B, Goupille P, McHugh N, Rodevand E, Holck P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis. 2010;69:394–399.
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Gregoriou S, Lazaridou E, Belyayeva E, Apalla Z, Makris M, et al. Treatment of nail psoriasis with adalimumab: an open label unblinded study. J Eur Acad Dermatol Venereol. 2010;24:530–534.
   PubMed Web of Science ®Google Scholar
• Sola-Ortigosa J, Sanchez-Regana M, Umbert-Millet P. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice. J Dermatolog Treat. 2011 [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Luger TA, Barker J, Lambert J, Yang S, Robertson D, Foehl J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2009;23:896–904.
   PubMed Web of Science ®Google Scholar
• Barrera MV, Habicheyn S, Mendiola MV, Herrera CE. Etanercept in the treatment and retreatment of psoriasis in daily clinical practice. Eur J Dermatol. 2008;18:683–687.
   PubMed Web of Science ®Google Scholar